Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.45 |
| ▸ | HTR2B | P41595 | 12/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631762 | 0.89 | HTR2C (0.46) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| SCHEMBL5630863 | 0.89 | HTR2C (0.46) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| SCHEMBL5630855 | 0.89 | HTR2C (0.46) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5632710 | 0.87 | HTR2C (0.45) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5632713 | 0.87 | HTR2C (0.45) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| SCHEMBL5633102 | 0.82 | HTR2C (0.41) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| SCHEMBL5632697 | 0.82 | ADRB1 (0.49) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL5630914 | 0.82 | ADRB1 (0.49) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL5631014 | 0.82 | HTR2C (0.41) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| SCHEMBL5632745 | 0.82 | HTR2C (0.41) | HTR2CHTR2BHTR2AHTR6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HTR2C 3663/4885HTR2B 3637/4885HTR2A 4298/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HTR2C 3663/4885HTR2B 3637/4885HTR2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.